Loading...
  • SynAct Pharma logoSVE
  • SynAct Pharma logoENG
  • About us
    • The Company in brief
    • Vision
    • History
    • Organisation
    • New Partnerships
  • Our Science
    • Resolving Inflammation
    • Selective Melanocortin Stimulation
    • Scientific Advisory Board
  • Pipeline
    • Pipeline Overview
    • The AP1189 Development Program
    • Rheumatoid Arthritis
    • Membranous Nephropathy
    • Virus Induced Respiratory Insufficiency
    • Ongoing clinical studies
  • Investors
    • Listing Nasdaq 2022
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
  • Governance
    • General Meetings
    • Corporate Governance Report
    • Nomination Committee
      • Nomination Committees
    • Board of Directors
      • Remuneration Committee
      • Audit Committee
    • Management
    • Auditor
    • Articles of Association
    • Code of Conduct
  • Media
    • Press Releases
    • Synact in Media
    • Image Bank
    • Subscribe
  • Contact
  • Listing Nasdaq 2022

Calendar

Upcoming events
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • All years
  • 04
    Nov
    November 4, 2022
    Interim Report Q3 2022
    Add to calendar
  • 17
    Feb
    February 17, 2023
    Annual Results 2022
    Add to calendar
  • 05
    May
    May 5, 2023
    Interim Report Q1 2023
    Add to calendar
  • 04
    Jul
    July 4, 2023
    World Congress of Basic & Clinical Pharmacology 2023 – Thomas Jonassen presents AP1189 at a symposium on Resolution Therapy.
    Add to calendar
  • Investors
    • Listing Nasdaq 2022
    • Rights Issue 2022
    • Word from the CEO
    • Financial Reports
    • Investment highlights
    • Presentations
    • The Share
      • Share price development
      • Ownership Structure
      • Share Capital Development
    • Analyst Coverage
    • Calendar
    • Press Releases
    • Prospectuses
Jeppe Øvlesen, MBA.
Jeppe Øvlesen, MBA.
Chief Executive Officer
+45 28 44 75 67
joo@synactpharma.com
Patrik Renblad, MSc.
Patrik Renblad, MSc.
Chief Financial Officer
+4670 747 97 68
par@synactpharma.com

About Synact Pharma

SynAct Pharma is a clinical stage biotechnology company focused on resolving inflammation with melanocortin biology. Selective activation of the melanocortin system can help the immune system resolve excessive or chronic inflammation.

  • Privacy Policy
  • Cookies

Explore our Website

  • About us
  • Our Science
  • Pipeline
  • Investors
  • Governance
  • Media
  • Contact
  • Listing Nasdaq 2022
  • LinkedIn

Subscribe